Address correspondence to:
Prakash C. Deedwania, MD, FACC, FACP, FAHA
Chief, Cardiology Section
UCSF Program at Fresno
2615 E. Clinton Avenue (111)
Fresno, CA 93703
Telephone: 559-228-5325
Fax: 559-228-6961
Email: [email protected]

Abstract: African American, Hispanic, South Asian, and Pima Indian populations are at high risk for cardiovascular mortality and morbidity, partly owing to greater prevalence of diabetes and obesity. Angiotensin-converting enzyme inhibitors and angiotensin receptor blockers are the treatment of choice for patients with diabetes at high risk for cardiovascular events. Early reports suggest dual renin-angiotensin system blockade is as effective as monotherapy in high-risk patients; further studies will determine if it increases cardioprotective effects in patients with chronic kidney disease, diabetes, and heart failure.

Key Words: Ethnicity, angiotensin-converting enzyme inhibitor, angiotensin receptor blocker, diabetes, cardioprotection


Continue Reading

Disclosure: Dr. Deedwania is a consultant for Boehringer Ingelheim, a consultant/speaker for AstraZeneca, and a consultant/speaker for Novartis. Mary Ellen Shepard, Clinical CONNEXION (Newtown, Pennsylvania), provided editorial assistance. Boehringer Ingelheim Pharmaceuticals, Inc. provided editorial support. This work was supported by Boehringer Ingelheim Pharmaceuticals, Inc.